CorMedix Inc. CRMD · NASDAQ
$7.26 -2.68% (-$0.20)
Summary
88 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 40 USD is left as net profit.
- Revenue grew by 1,583% a year over the last 3 years.
- It earns 28 USD a year on every 100 USD of invested capital.
- It holds more cash than debt: $256.7M against $145.2M.
What to watch
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 3.1 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 320% a year over 5 years. Over the last 3 years it grew by 1,583% a year.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 17 USD
- Research and development 6.0 USD
- Sales and administration 30 USD
- Taxes and other 6.5 USD
- Net profit 40 USD
Net profit, industry median (Biotechnology) -7.1 USD
Out of every 100 USD of revenue, 40 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 8
- Hold 0
- Sell 0
Today's price within the analysts' price targets
The average target of $14.5 is 100% above today's price. 100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 100%
By region
- Europe 100%
Product brings in 100% of revenue.
Segments in detail